MedTrace Logo

Intratumoural Injection of a Novel NanoZolid®-Docetaxel Depot Formulation in Patients With Advanced Solid Tumours

NCT04810208 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2021-12-30

No results posted yet for this study

Summary

This is a multicentre, open-label, first in man, study of a novel NanoZolid®-docetaxel depot formulation (NZ-DTX Depot) given as an intra-tumoural injection in patients with advanced solid tumours. The study includes a dose escalation part and a dose expansion part.

Conditions

Interventions

DRUG

Docetaxel

Docetaxel in NanoZolid formulation, for intratumoural injection

Sponsors & Collaborators

  • Lidds AB

    lead INDUSTRY

Principal Investigators

  • Charlotta Gauffin, PhD · Lidds AB

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-28
Primary Completion
2021-10-07
Completion
2021-10-07

Countries

  • Denmark
  • Lithuania
  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04810208 on ClinicalTrials.gov